Singapore markets open in 35 minutes

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
840.14-9.04 (-1.06%)
At close: 04:00PM EST
841.90 +1.76 (+0.21%)
After hours: 07:54PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 91.53B
Enterprise value 84.32B
Trailing P/E 23.96
Forward P/E 19.53
PEG Ratio (5 yr expected) 1.81
Price/sales (ttm)7.30
Price/book (mrq)3.68
Enterprise value/revenue 6.44
Enterprise value/EBITDA 17.36

Trading information

Stock price history

Beta (5Y monthly) 0.14
52-week change 313.15%
S&P500 52-week change 315.38%
52-week high 3853.97
52-week low 3668.00
50-day moving average 3813.33
200-day moving average 3786.56

Share statistics

Avg vol (3-month) 3454.25k
Avg vol (10-day) 3536.66k
Shares outstanding 5107.13M
Implied shares outstanding 6108.95M
Float 8101.75M
% held by insiders 12.55%
% held by institutions 189.31%
Shares short (14 Nov 2023) 41.4M
Short ratio (14 Nov 2023) 42.74
Short % of float (14 Nov 2023) 41.53%
Short % of shares outstanding (14 Nov 2023) 41.28%
Shares short (prior month 12 Oct 2023) 41.37M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)29 Sept 2023

Profitability

Profit margin 30.47%
Operating margin (ttm)36.01%

Management effectiveness

Return on assets (ttm)9.21%
Return on equity (ttm)17.22%

Income statement

Revenue (ttm)13.1B
Revenue per share (ttm)122.63
Quarterly revenue growth (yoy)14.50%
Gross profit (ttm)7.02B
EBITDA 4.82B
Net income avi to common (ttm)3.99B
Diluted EPS (ttm)35.03
Quarterly earnings growth (yoy)-23.40%

Balance sheet

Total cash (mrq)9.91B
Total cash per share (mrq)93.22
Total debt (mrq)2.7B
Total debt/equity (mrq)10.85%
Current ratio (mrq)5.18
Book value per share (mrq)234.46

Cash flow statement

Operating cash flow (ttm)5.22B
Levered free cash flow (ttm)3.53B